Last reviewed · How we verify
gemcitabine,nimotuzumab, toripalimab
gemcitabine,nimotuzumab, toripalimab is a Nucleoside analog, Monoclonal antibody, PD-1 inhibitor Small molecule drug developed by Air Force Military Medical University, China. It is currently in Phase 3 development for Non-small cell lung cancer, Pancreatic cancer, Head and neck cancer. Also known as: GNT.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while nimotuzumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and toripalimab is a PD-1 inhibitor.
Gemcitabine is a nucleoside analog that inhibits DNA synthesis, while nimotuzumab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), and toripalimab is a PD-1 inhibitor. Used for Non-small cell lung cancer, Pancreatic cancer, Head and neck cancer.
At a glance
| Generic name | gemcitabine,nimotuzumab, toripalimab |
|---|---|
| Also known as | GNT |
| Sponsor | Air Force Military Medical University, China |
| Drug class | Nucleoside analog, Monoclonal antibody, PD-1 inhibitor |
| Target | DNA, EGFR, PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Gemcitabine works by incorporating itself into DNA, causing DNA damage and inhibiting cancer cell growth. Nimotuzumab binds to EGFR, preventing it from interacting with its ligands and thereby inhibiting tumor growth. Toripalimab binds to PD-1, preventing it from interacting with its ligands and thereby inhibiting the immune system's ability to recognize and attack cancer cells.
Approved indications
- Non-small cell lung cancer
- Pancreatic cancer
- Head and neck cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Fatigue
- Nausea
- Vomiting
- Diarrhea
- Rash
- Pruritus
- Hypersensitivity reactions
Key clinical trials
- Nimotuzumab Combined With TGP as First-line Therapy in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma (PHASE2)
- TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma (PHASE3)
- GNT Induction Treatment in Locally Advanced NPC (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- gemcitabine,nimotuzumab, toripalimab CI brief — competitive landscape report
- gemcitabine,nimotuzumab, toripalimab updates RSS · CI watch RSS
- Air Force Military Medical University, China portfolio CI
Frequently asked questions about gemcitabine,nimotuzumab, toripalimab
What is gemcitabine,nimotuzumab, toripalimab?
How does gemcitabine,nimotuzumab, toripalimab work?
What is gemcitabine,nimotuzumab, toripalimab used for?
Who makes gemcitabine,nimotuzumab, toripalimab?
Is gemcitabine,nimotuzumab, toripalimab also known as anything else?
What drug class is gemcitabine,nimotuzumab, toripalimab in?
What development phase is gemcitabine,nimotuzumab, toripalimab in?
What are the side effects of gemcitabine,nimotuzumab, toripalimab?
What does gemcitabine,nimotuzumab, toripalimab target?
Related
- Drug class: All Nucleoside analog, Monoclonal antibody, PD-1 inhibitor drugs
- Target: All drugs targeting DNA, EGFR, PD-1
- Manufacturer: Air Force Military Medical University, China — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Pancreatic cancer
- Indication: Drugs for Head and neck cancer
- Also known as: GNT
- Compare: gemcitabine,nimotuzumab, toripalimab vs similar drugs
- Pricing: gemcitabine,nimotuzumab, toripalimab cost, discount & access